U.S. Contraceptives Market - By Product, By Age Group, By Distribution Channel - Forecast, 2024 – 2032

U.S. Contraceptives Market Size

The U.S. contraceptives market was valued at around USD 7 billion in 2023 and is expected to exhibit growth at a CAGR of 7.2% from 2024 to 2032. Contraceptives or birth controls as they are commonly referred to, are any products or medications that avoid a pregnancy by purposely preventing or curtailing the probability of fertilization. This market bears methods of contraception such as condoms, IUDs, vaginal rings, pills, etc.
 

A broad category of this market is the increased adoption of long-acting reversible contraceptives (LARCs) which represent the use of IUDs and implants. Moreover, oral contraceptive pills are still dominant in the market but other products like non-hormonal gels are emerging that have strong appeal among those who avoid hormonal products.

The other major shift is the increased provision of contraceptive products without prescription (OTC). In 2023, the clearest indicator of this was the FDA's decision on Opill, a single progestin pill. This is likely to enhance ease of use, especially for younger women and those living in rural areas. It is also indicative of a wider movement towards policy change to eliminate contraceptive access barriers as seen with the Affordable Care Act's requirement to provide contraceptive coverage at no cost.
 

The effects of the COVID-19 pandemic have accelerated the use of telemedicine systems which have facilitated birth control prescription through the mail. Companies like Nurx and Planned Parenthood Direct provide these services. On the other hand, the male contraceptive industry is gradually developing, as attempts have commenced for male non-hormonal contraceptive clinical trials, namely the Vasalgel injection. Unfortunately, availability will not be applicable for many years. These trends specify an emerging market that focuses on accessibility, innovation, and increasing consumer needs.
 

U.S. Contraceptives Market Trends

Notable trends are observed in the U.S. contraceptive market because of changing consumer habits, technological innovations, and policy regulations. Among the most considerable trends is the surging popularity and utilization in the US of long-acting reversible contraceptives (LARCs) such as intrauterine devices (IUDs) and subdermal implants. These methods possess the highest utilization among many women because they are easy to use and very effective once inserted. For example, the IUD segment is certainly expected to witness growth spurred by Bayer's Mirena and CooperSurgical's ParaGard, as well as the major brands.
 

• Telemedicine revolution is also changing the dynamics of the contraceptives marketplace. Companies like Nurx and Planned Parenthood Direct have set the standards for selling birth control pills and allow consultations via the internet. The work is both appealing and convenient, especially to those who are tech minded. Reports of the Guttmacher Institute state that in 2019 only 10% of women who used contraception selected telemedicine, but by 2023 that number had increased to almost 29%.
   
• Additionally, different types of men's contraceptives, which are still experimental, suggest a wider market view that may promote gender equity in contraceptive responsibility. Innovation in contraceptive methods is another defining shift. The market's acceptance of Annovera, a reusable vaginal ring that provides a year worth of contraception proves the market's adoption to solutions that are both effective and user friendly.
   
• As innovation matures, the market will be expanding towards Annovera type products that offer better usability paired with efficacy. Innovations in the male end of the contraceptive market, although still in the experimental stage, suggest wider scope in the market.
   
• Making prescription contraceptives available OTC is a step by the FDA in the right direction as it increases the availability of the drug to individuals seeking it. For instance, Opill, a daily birth control pill, was recently approved. It is expected to be widely used by people that have limited access to healthcare services, thereby significantly improving their availability.
   

U.S. Contraceptives Market Analysis

Based on product type, the market is bifurcated into drugs and devices. The drugs segment dominated the market with a revenue of around USD 3.8 billion in 2023.
 

• Individuals find it easier to plan for births and space their children such that their personal circumstances are considered. When taken properly and consistently, contraceptive drugs can drastically reduce the chances of getting pregnant.
   
• Contraceptive drugs are self-explanatory. They can be easily used by women without medical assistance. For instance, oral contraceptive pills or patches are administered and used by women at home. This helps individuals exercise their autonomy with respect to their family planning initiatives.
   
• The other major factor is the introduction of new and better contraceptive formulations that attempt to relieve user concerns about side effects or effectiveness. There is growing popularity of pill innovations such as the typical extended cycle pill that lessens the number of menstrual periods or the low hormonal dose that seeks to reduce negative effects. The FDA approving new hormone products – such as the Annovera, an extended-cycle pill – demonstrates the increased demand for convenience and flexibility among users.
   

Based on age group, the U.S. contraceptives market is branched into 15-44 years, and above 44 years. The 15-44 years segment dominated the market with a revenue of around USD 6.5 billion in 2023.
 

• The ages 15-44 are usually considered the age of reproduction or childbearing years. This group highly influences the need for contraceptives. Young people, including adolescents, are sexually active, but with respect to educational, professional, and personal goals, most are not ready to start families. Hence, their contraceptive use is targeted at avoiding unwanted pregnancies as they pursue other life objectives.
   
• Members of this age group tend to have greater mobility, which increases their chances of accessing healthcare facilities or services, making it more convenient for them to get contraceptives. Moreover, some contraceptives have health benefits apart from pregnancy prevention like the reduction of certain cancers such as ovarian and endometrial. Many health practitioners provide contraception services and counseling to enhance informed consent.

Based on distribution channel, the U.S. contraceptives market is segmented into retail pharmacies, hospital pharmacies, online channels, and other distribution channels. The retail pharmacies segment dominated the market in 2023 with a share of 45.9%.
 

• Contraceptives are available without a prescription, which makes retail pharmacies very popular among the public. It is easy for people to access inexpensive pharmacies in their vicinity and therefore get contraceptives without prior consultation. This enhances their usage and consequently increases demand in the market.
   
• Regardless of if a patient has a prescription or not, retail pharmacies are able to sell both prescription and non-prescription contraceptives. They tend to offer sales, discounts, and loyalty promotions aimed at increasing the uptake of contraceptives which makes these products more accessible.
   
• In some cases, retail pharmacies can directly bill insurance companies for prescription contraceptives, thus making it easier for people to access it. In addition, the public and educational focus on reproductive health issues on the part of nonprofit organizations and other community-based health initiatives has greatly improved for the underserved populations.

The East South Central contraceptives market accounted for USD 1.7 billion market revenue in 2023 and is anticipated to grow at CAGR of 7.9% between 2024 – 2032 period.
 

• The desire for contraceptive products is rising across many regions due to the high levels of unplanned pregnancies and the increased family planning education. In the East South-Central area, government efforts and public health marketing are vital in increasing the availability of contraceptive products.
   
• Another important factor for this region is the growing acceptance of long-acting reversible contraceptives (LARCs) like IUDs and implants. LARCs have gained acceptance recently because of their ease in usage and high effectiveness. For this reason, many healthcare professionals are providing them as a means to curb unplanned pregnancies.
   
• In addition, awareness and understanding of education on reproductive health have been increased by non-profit organizations and community-focused health programs, especially for those with less access to healthcare facilities.
   

West South-Central contraceptives market is projected to grow remarkably in the coming years.
 

• The West South-Central contraceptives market, encompassing Texas, Louisiana, Oklahoma, and Arkansas, is expected to grow remarkably due to several key drivers. Population growth and a large reproductive-age demographic in states like Texas, the second most populous U.S. state, are primary factors fueling demand for contraceptives. Growing awareness of family planning and sexual health in both urban and rural areas is also driving the market, with increased education efforts from public health organizations and clinics like Planned Parenthood playing a significant role.
   
• Another key driver is the focus on improving access to contraceptives through Medicaid expansions and government-backed programs. In Texas, initiatives like the Healthy Texas Women Program provide free birth control to low-income women, significantly boosting access to various contraceptive methods.
   
• Additionally, changing social and cultural attitudes around reproductive health are influencing the market, with younger generations seeking more control over family planning and reproductive choices. Despite regional challenges around access to reproductive healthcare, efforts to expand contraceptive access and the growth of e-commerce channels for contraceptive distribution are expected to continue driving market growth in the West South-Central region.
   

U.S. Contraceptives Market Share

Numerous businesses compete in the market. As with other LARCs, intrauterine devices (IUDs) and contraceptive implants are gaining traction in the market because of their effectiveness and long-term use - most people prefer them. Besides LARCs, birth control pills still rank among the most used methods of contraception. The entry of telemedicine offered by platforms such as Nurx and SimpleHealth is changing the dynamics of the market by making contraceptives easily obtainable. Not only has the rise of e-commerce captured a portion of the market, but younger consumers having online prescriptions is also contributing to the expansion of different market segments.
 

• Companies such as Teva Pharmaceuticals, Bayer AG, and Pfizer Inc. offer comprehensive contraceptive product portfolios, including oral pills, injectables, implants, intrauterine devices (IUDs), and emergency contraceptives. Their product ranges encompass both hormonal and non-hormonal contraceptives, providing complete contraceptive solutions.
   
• These companies prioritize research and development in long-acting reversible contraceptives (LARCs), particularly IUDs and implants. Products such as Bayer's Mirena IUD demonstrate their commitment to developing effective, user-friendly contraceptive solutions with extended duration of action.
   

U.S. Contraceptives Market Companies

Some of the eminent market participants operating in the U.S. contraceptives industry include:

• Allergan (AbbVie, Inc.)
• Ani Pharmaceuticals
• Bayer AG
• CooperSurgical Inc
• Church and Dwight Co, Inc.
• Johnson and Johnson
• Mayer Laboratories, Inc.
• Merck and Co., Inc.
• Meril Life Sciences Pvt. Ltd.
• Perrigo Company
• Pfizer, Inc.
• Pregna International Ltd.
• Reckitt Benckiser Group Plc.
• Teva Pharmaceuticals Industries Ltd.
• Veru Inc.
   

U.S. Contraceptives Industry News:

• In October 2022, Bayer received a grant from the Bill and Melinda Gates Foundation to support the development of non-hormonal contraceptive methods. This partnership enhanced the research in this area, reflecting Bayer's commitment to expanding contraceptive options.
   
• In December 2022, CooperSurgical, Inc. announced a strategic partnership with Ostro to launch a new consumer engagement solution for CooperSurgical's hormone-free IUD, Paragard. This partnership helped the company incorporate advanced technology including live nurse navigator to assist patients and Paragard users, as a result enhancing their customer base and gaining a technological advantage over its peers.
   

The U.S. contraceptives market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Drugs
  • Oral contraceptive pills
  • Injectable contraceptives
  • Topical contraceptives
• Devices
  • Intra-uterine devices
    • Hormonal IUD
    • Copper IUD
  • Condoms
    • Male
    • Female
  • Subdermal implants
  • Vaginal rings
  • Diaphragms
  • Contraceptive sponges

Market, By Age Group

• 15-44 years
• Above 44 years

Market, By Distribution Channel

• Retail pharmacies
• Hospital pharmacies
• Online channels
• Other distribution channels

The above information is provided for the following zones:

• East North Central
• West South Central
• South Atlantic
• Northeast
• East South Central
• West North Central
• Pacific Central
• Mountain States